Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Marcus Bahra

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5013965318, A5111078749. Sources: OpenAlex.

Their work

Papers
50 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
104
Papers, trials and grants by year

2012: 3 papers · 2013: 4 papers · 2014: 7 papers · 2015: 5 papers · 2016: 3 papers · 2017: 5 papers · 2018: 5 papers · 2019: 2 papers · 2020: 2 papers · 2021: 5 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 4 papers

Papers 50

  1. Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. Co-author DOI 10.1002/cam4.71490↗
  2. The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pan… Co-author DOI 10.1016/j.ejca.2025.116189↗
  3. Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer models. Co-author DOI 10.1038/s41598-026-47856-1↗
  4. Diagnostic Performance of Node-RADS for CT-based Assessment of Regional Lymph Nodes in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-9115727/v1↗
  5. Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. Co-author DOI 10.1186/s12935-025-03969-7↗
  6. Placental growth factor promotes neural invasion and predicts disease prognosis in resectable pancreatic cancer. Co-author DOI 10.1186/s13046-024-03066-z↗
  7. DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites. Co-author DOI 10.1186/s13148-024-01768-x↗
  8. Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised cl… Co-author DOI 10.1016/j.ejca.2022.12.009↗
  9. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Co-author DOI 10.1038/s41467-021-27088-9↗
  10. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma -… Co-author DOI 10.1016/j.ejca.2021.03.036↗
  11. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
  12. Cancer Associated Fibroblasts Derived from Pancreatic Adenocarcinoma and Their Role in Cell Migration. Co-author DOI 10.21873/anticanres.15227↗
  13. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Co-author DOI 10.3389/fonc.2021.670396↗
  14. Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Secondary Resection? Co-author DOI 10.3390/medicina57010077↗
  15. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic can… Co-author DOI 10.1016/j.ejca.2020.06.032↗
  16. TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO… Co-author DOI 10.1158/1078-0432.ccr-19-3034↗
  17. Split-bolus vs. multiphasic contrast bolus protocol in patients with pancreatic cancer or cholangiocarcinoma. Co-author DOI 10.1016/j.ejrad.2019.07.027↗
  18. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis. Co-author DOI 10.21873/anticanres.13781↗
  19. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospecti… Co-author DOI 10.1016/j.ejca.2018.06.001↗
  20. Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. Last author DOI 10.1016/j.ejso.2018.05.002↗
  21. Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2018.09.004↗
  22. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Last author DOI 10.1016/j.suronc.2018.09.004↗
  23. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  24. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.016↗
  25. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.034↗
  26. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Ra… First author DOI 10.1200/jco.2017.72.6463↗
  27. Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. Co-author DOI 10.1371/journal.pone.0186341↗
  28. Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in Patien… Last author DOI 10.21873/anticanres.11952↗
  29. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Co-author DOI 10.1016/j.prp.2016.06.001↗
  30. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.4038↗
  31. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. First author DOI 10.4251/wjgo.v8.i3.248↗
  32. Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. First author DOI 10.1002/jso.23951↗
  33. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treat… Co-author DOI 10.1016/j.ejca.2015.05.005↗
  34. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicat… Co-author DOI 10.1097/mpa.0000000000000248↗
  35. Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000365↗
  36. CT and MRI Findings of Autoimmune Polymorph Bifocal Pancreatitis Mimicking Pancreatic Adenocarcinoma: A Case Report and Review of the Literature. Co-author DOI 10.1177/2324709615576988↗
  37. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Co-author DOI 10.1038/bjc.2014.495↗
  38. Radiologic resectability assessment in pancreatic cancer. Last author DOI 10.1055/s-0033-1350190↗
  39. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Co-author DOI 10.1093/annonc/mdu084↗
  40. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000077↗
  41. Intensity-modulated and image-guided radiotherapy in patients with locally advanced inoperable pancreatic cancer after preradiation chemotherapy. Co-author DOI 10.1155/2014/452089↗
  42. Axon guidance factor SLIT2 inhibits neural invasion and metastasis in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-13-1012↗
  43. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. Co-author DOI 10.1186/1471-2407-14-204↗
  44. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. Co-author DOI 10.1002/jso.23409↗
  45. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/1471-2407-13-450↗
  46. Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Co-author DOI 10.3389/fonc.2013.00155↗
  47. Blood group determinates incidence for pancreatic cancer in Germany. Co-author DOI 10.3389/fphys.2013.00118↗
  48. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Co-author DOI 10.1111/j.1365-2559.2012.04225.x↗
  49. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Last author DOI 10.1155/2012/939350↗
  50. Postoperative complications deteriorate long-term outcome in pancreatic cancer patients. Last author DOI 10.1245/s10434-011-2041-4↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Uwe Pelzer · 34 shared papers, 2012–2026 · strength 3.11
  2. Marianne Sinn · 23 shared papers, 2013–2022 · strength 1.41
  3. Christopher Neumann · 7 shared papers, 2018–2026 · strength 1.28
  4. Hanno B. Riess · 22 shared papers, 2012–2021 · strength 1.27
  5. Matthäus Felsenstein · 6 shared papers, 2018–2026 · strength 1.12
  6. Jana Käthe Striefler · 17 shared papers, 2012–2022 · strength 1.06
  7. Mihnea Paul Dragomir · 5 shared papers, 2024–2026 · strength 1.06
  8. Helmut Oettle · 14 shared papers, 2013–2023 · strength 0.99
  9. Bruno Valentin Sinn · 14 shared papers, 2012–2024 · strength 0.81
  10. Fritz Klein · 11 shared papers, 2012–2021 · strength 0.79
  11. Katharina Wansch · 3 shared papers, 2025–2026 · strength 0.67
  12. Florian Dölvers · 3 shared papers, 2025–2026 · strength 0.67
  13. François Schneider · 3 shared papers, 2025–2026 · strength 0.67
  14. Carsten Denkert · 12 shared papers, 2012–2021 · strength 0.66
  15. Thomas Malinka · 5 shared papers, 2018–2024 · strength 0.59
  16. Timm Denecke · 8 shared papers, 2014–2018 · strength 0.55
  17. Rosa Bianca Schmuck · 6 shared papers, 2014–2021 · strength 0.49
  18. Carsten Kamphues · 6 shared papers, 2012–2026 · strength 0.44
  19. Philipp Lohneis · 7 shared papers, 2014–2021 · strength 0.44
  20. Jens Stieler · 9 shared papers, 2013–2017 · strength 0.37
  21. Wilko Weichert · 7 shared papers, 2012–2018 · strength 0.30
  22. Albrecht Stenzinger · 7 shared papers, 2012–2018 · strength 0.27
  23. Rolf Reiter · 1 shared paper, 2026 · strength 0.27
  24. Florian Nino Loch · 1 shared paper, 2026 · strength 0.27
  25. Ingolf Sack · 1 shared paper, 2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.